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Letters
RESEARCH LETTER
Use of Genetic Testing in Amyotrophic Lateral
Sclerosis byNeurologists
There have been a number of publications describing the
important role of genetic counseling in amyotrophic lateral
sclerosis (ALS).1,2 While such attempts at guiding who
should undergo genetic testing are welcome, they are put
forth in a vacuum because there are no data on where ALS
neurologists stand in terms of genetic testing and counsel-
ing for the disease, and in terms of what is considered to be
familial and sporadic ALS.3 We attempted to fill this gap by
surveying members of the Northeast Amyotrophic Lateral
Sclerosis Consortium (NEALS, http://www.alsconsortium
.org), one of the largest clinical research organizations
for ALS.
We sought tounderstand inwhich situations genetic test-
ing is used, which genes are tested for, and the attitudes of
respondents toward genetic testing and counseling.
Methods | The survey was sent via email on June 20, 2016, to
134 principal investigators who are members of NEALS. The
deadline for survey completion was July 29, 2016. Data were
collated and analyzed usingMicrosoft Excel (Table). The NIH
Office of Human Subjects Research Protection has deter-
mined that this type of research falls under exemption for
institutional review board approval.
Results | We obtained 43 responses, resulting in a response
rate of nearly one-third (32.1%). Responses were obtained
from centers throughout the United States as well as from
Canada, Israel, and Lebanon. The mean annual number of
ALS patients seen at each site was 157 (range, 20-500). Forty
respondents (93.0%) reported that they screen familial ALS
cases for genetic mutations in their routine clinical practice
and 13 (30.2%) screen sporadic cases. Genetic testing rates
are surprisingly lower in the context of clinical research:
only 31 respondents (72.1%) reported that they screen famil-
ial ALS cases for genetic mutations in preparation for their
enrollment in clinical trials, while only 8 (18.6%) screen
sporadic cases in clinical trials.
One respondent did not perform genetic testing for clini-
cal trials or everyday clinical practice, and 1 respondent did
not specify which genes the site tested for. Of the 41 respon-
dents who specified which genes were tested for, 100%
screened for C9ORF72 (Figure). The next most common
gene screened for was SOD1, with 31 respondents (75.6%).
Other genes reported are shown, by prevalence in testing, in
the Figure. Of note, 2 respondents reported testing for
Ataxin 2 in addition to other genes.
Just fewer than half of respondents (n = 21; 48.8%)
reported using next-generation sequencing techniques at
their sites. More than half of respondents (n = 24; 55.8%)
reported using panel testing. Only 14 of the 24 respondents
(58.3%) who reported using Sanger sequencing-based panel
testing believed it to be cost-effective. Most respondents
(n = 42; 97.7%) provide genetic counseling to ALS patients,
with only 1 respondent denying the use of genetic counsel-
ing. Finally, the overwhelming majority of respondents
(n = 39; 90.7%) would change their attitude toward genetic
testing if an effective therapy for ALS became available.
Discussion | The importance of genetic testing in ALS is shown
bytheresponse to thequestiononwhether futuregenetherapy
Table. Survey Questions and Responses of NeurologistsWho Study
Amyotrophic Lateral Sclerosis (ALS) (N = 43)
Question Yes No
No
Response
Do you screen familial ALS cases for genetic
mutations for clinical trials?
31 11 1
Do you screen sporadic ALS cases for genetic
mutations for clinical trials?
8 34 1
Do you screen familial ALS cases for genetic
mutations in everyday clinical practice?
40 3 0
Do you screen sporadic ALS cases for genetic
mutations in everyday clinical practice?
13 30 0
Do you use next-generation sequencing
techniques such as exome sequencing?
21 17 5
Do you use genetic panel testing? 24 17 2
Do you believe panel testing is cost-effective? 18 22 3
Do you provide genetic counseling to patients? 42 1 0
Would your attitude toward genetic testing
change if an effective gene therapy
became available?
39 4 0
Figure. Results of a Survey Conducted on Genetic Testing
AmongMembers of the Northeast ALS Consortium (n = 41)
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Percentage of respondents who reported testing for each gene specified in the
survey. The total number of respondents who reported testing for specific ALS
genes was 41 (of 43 who responded to the survey).
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trialswill influence thepracticeof genetic testing.Almostuni-
formly the answer was yes. Our data show that although cur-
rent efforts at genetic counseling guidelines for ALS patients
are important, thepaceofdiscovery in thegenetic fieldmeans
that these guidelines have a relatively short shelf life. Guide-
line documents need to operate in a dynamic manner with
yearly updates, rather than being viewed as dogma.
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